Imaging in Hypertrophic Cardiomyopathy: Beyond Risk Stratification

Zachariah Nealy; Christopher Kramer

doi:10.1016/j.hfc.2023.03.004

Imaging in Hypertrophic Cardiomyopathy: Beyond Risk Stratification

Heart Fail Clin. 2023 Oct;19(4):419-428. doi: 10.1016/j.hfc.2023.03.004. Epub 2023 Apr 29.

Authors

Zachariah Nealy¹, Christopher Kramer²

Affiliations

¹ Cardiovascular Division, Department of Medicine, University of Virginia Health, Charlottesville, VA 22908, USA.
² Cardiovascular Division, Department of Medicine, University of Virginia Health, Charlottesville, VA 22908, USA; Department of Radiology and Medical Imaging, University of Virginia Health, Charlottesville, VA 22908, USA. Electronic address: ckramer@virginia.edu.

PMID: 37714584
PMCID: PMC10800026 (available on 2024-10-01)
DOI: 10.1016/j.hfc.2023.03.004

Abstract

A multimodality imaging evaluation in hypertrophic cardiomyopathy is often used for risk stratification. Recent developments in imaging have allowed for better diagnosis, prognosis, and decision-making for a variety of therapies from medical to interventional. Echocardiography and magnetic resonance have been integral in evaluating subtype, left ventricular function, tissue characterization, left atrial measurements, valvular function, and presence of left ventricular aneurysm and outflow tract obstruction. These factors have helped to quantify risk of atrial fibrillation and determine the likely usefulness of pharmacologic therapy and septal reduction therapy. This review covers these in detail.

Keywords: CMR; Echocardiography; Hypertrophic cardiomyopathy; Imaging.

Publication types

Review

MeSH terms

Atrial Fibrillation*
Cardiomyopathy, Hypertrophic* / diagnostic imaging
Echocardiography
Humans
Multimodal Imaging
Risk Assessment

Abstract

Publication types

MeSH terms

Grants and funding